A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)

Journal of the Anus, Rectum and Colon
doi 10.23922/jarc.2018-043
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Japan Society of Coloproctology

Related search

Phase I Study of TAS-102 and Irinotecan Combination Therapy in Japanese Patients With Advanced Colorectal Cancer

Investigational New Drugs
OncologyPharmacology
2015English

Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study

Clinical Colorectal Cancer
OncologyGastroenterology
2016English

Phase I Study of TAS-102 Treatment in Japanese Patients With Advanced Solid Tumours

British Journal of Cancer
Cancer ResearchOncology
2012English

Phase II Trial of UFT in Advanced Colorectal and Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
1990English

A Systematic Review and Network Meta‐Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Gemcitabine Plus Vinorelbine as First-Line Chemotherapy in Advanced Nonsmall Cell Lung Carcinoma a Phase II Trial

Cancer
Cancer ResearchOncology
2000English

Phase I–II Trial of Prolonged Gemcitabine Infusion Plus Paclitaxel as a Biweekly Schedule for Advanced Breast Cancer Patients Pretreated With Anthracyclines

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy